iifl-logo-icon 1

Lyka Labs Ltd Share Price

141.93
(-3.13%)
Oct 21, 2024|03:33:40 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open147.8
  • Day's High149.49
  • 52 Wk High172.5
  • Prev. Close146.51
  • Day's Low141.01
  • 52 Wk Low 97.9
  • Turnover (lac)100.14
  • P/E417.71
  • Face Value10
  • Book Value35.94
  • EPS0.35
  • Mkt. Cap (Cr.)506.55
  • Div. Yield0
View All Historical Data
No Records Found

Lyka Labs Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

147.8

Prev. Close

146.51

Turnover(Lac.)

100.14

Day's High

149.49

Day's Low

141.01

52 Week's High

172.5

52 Week's Low

97.9

Book Value

35.94

Face Value

10

Mkt Cap (₹ Cr.)

506.55

P/E

417.71

EPS

0.35

Divi. Yield

0

Lyka Labs Ltd Corporate Action

18 Jan 2024

12:00 AM

EGM

arrow

15 Jul 2024

12:00 AM

BookCloser

arrow

4 Oct 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

15 Jul 2024

12:00 AM

AGM

Announcement Date: 15 Jul, 2024

arrow

Lyka Labs Ltd NEWS AND UPDATE

Top 10 stocks for today - 15th October 2024
15 Oct 2024|08:54 AM

Here are some of the stocks that may see significant price movement today: Reliance Industries, HCLTech, Sunteck Realty, etc.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Lyka Labs Ltd SHAREHOLDING SNAPSHOT

22 Oct, 2024|07:13 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 58.10%

Foreign: 0.00%

Indian: 58.10%

Non-Promoter- 0.82%

Institutions: 0.82%

Non-Institutions: 41.07%

Custodian: 0.00%

Share Price

Lyka Labs Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

42.16

48.13

28.69

28.69

Preference Capital

1.08

1.08

0.78

0.71

Reserves

57.17

28.3

15.75

-24.28

Net Worth

100.41

77.51

45.22

5.12

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

164.34

62.26

33.67

41.68

yoy growth (%)

163.95

84.92

-19.21

-46.56

Raw materials

-30.86

-23.52

-15.48

-21.53

As % of sales

18.77

37.77

45.99

51.66

Employee costs

-16.21

-13.02

-10.57

-10.89

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

64.9

-16.96

-24.24

-12.69

Depreciation

-15.38

-8.04

-5.64

-6.3

Tax paid

-20.33

3.93

-1.19

0.38

Working capital

29.28

5.11

-23.18

16.67

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

163.95

84.92

-19.21

-46.56

Op profit growth

575.87

-742.93

333.98

-102.37

EBIT growth

887.98

-262.21

7.28

-127.49

Net profit growth

-375.97

-72.81

390.71

5,718.25

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

111.19

93.07

194.08

86.25

61.49

Excise Duty

0

0

0

0

0

Net Sales

111.19

93.07

194.08

86.25

61.49

Other Operating Income

0

0

0

0

0

Other Income

1.45

3.4

2.09

1.56

3.09

Lyka Labs Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,897

163.494,55,021.88237.820.714,409.7498.75

Divis Laboratories Ltd

DIVISLAB

5,925

94.671,57,256.954300.512,063507.93

Cipla Ltd

CIPLA

1,523.75

30.971,22,988.411,055.940.853,752.25346.39

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,392.5

76.41,14,822.614690.832,394201.77

Dr Reddys Laboratories Ltd

DRREDDY

6,697.4

27.121,11,742.471,417.20.65,823.91,458.55

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Lyka Labs Ltd

Management

Register Office

Registrar Office

Managing Director & CEO

KUNAL NARENDRA GANDHI

Executive Director & CFO

Yogesh B Shah

Non-Exec. & Independent Dir.

Dhara P. Shah

Company Sec. & Compli. Officer

Kishore P Shah

Chairman & Independent Directo

Babulal Jain

Non Executive Director

Prashant Godha

Non Executive Director

Shashil Mendonsa

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Initially manufacturing formulations, Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. 83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company. The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders, anti-cancer products, cardio-vascular drugs and anti-inflammatory products. Lyka introduced, in India, cough lozenges containing dextromethorphan hydrobromide (DMR), favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification, it has invested in Relic Finance, a company carrying on the business of finance and merchant banking.A GOI-recognised Export House, it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year, it received an award from CHEMEXCIL for its outstanding performance.During 1997-98, the companys administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management system
Read More

Company FAQs

What is the Lyka Labs Ltd share price today?

The Lyka Labs Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹141.93 today.

What is the Market Cap of Lyka Labs Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lyka Labs Ltd is ₹506.55 Cr. as of 21 Oct ‘24

What is the PE and PB ratio of Lyka Labs Ltd?

The PE and PB ratios of Lyka Labs Ltd is 417.71 and 4.12 as of 21 Oct ‘24

What is the 52 Week High and Low of Lyka Labs Ltd?

The 52-week high/low is the highest and lowest price at which a Lyka Labs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lyka Labs Ltd is ₹97.9 and ₹172.5 as of 21 Oct ‘24

What is the CAGR of Lyka Labs Ltd?

Lyka Labs Ltd's CAGR for 5 Years at 53.79%, 3 Years at 14.93%, 1 Year at 29.91%, 6 Month at 10.93%, 3 Month at 24.91% and 1 Month at -5.58%.

What is the shareholding pattern of Lyka Labs Ltd?

The shareholding pattern of Lyka Labs Ltd is as follows:
Promoters - 58.10 %
Institutions - 0.82 %
Public - 41.08 %

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp